Boletin 66 - Segundo Cuatrimestre 2023

Detalles

 

 
 
 
 
 

Contenido destacado
Se ha publicado un resumen de evidencia


y un articulo de opinión

 

NOTICIAS

CAT 's

Nuevas Evidencias

Ahlberg R, Garcia-Argibay M, Taylor M, et al. 2023. Prevalence of sleep disorder diagnoses and sleep medication prescriptions in individuals with ADHD across the lifespan: a Swedish nationwide register-based study. BMJ Ment Health; 26:e300809.

Carr S, Hudson G, Amson N, et al. 2023. Service users’ experiences of social and psychological avoidable harm in mental health social care in England: Findings of a scoping review. The British Journal of Social Work, Volume 53, Issue 3, April 2023, Pages 1303–1324, https://doi.org/10.1093/bjsw/bcac209

Degenhardt L, Clark B, Macpherson G, et al. 2023. Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies. The Lancet Psychiatry. Volume 10, Issue 6, P386-402, June 2023. https://doi.org/10.1016/S2215-0366(23)00095-0 

Fazel M, Soneson E, Sellars E. et al. 2023. Partnerships at the Interface of Education and Mental Health Services: The Utilisation and Acceptability of the Provision of Specialist Liaison and Teacher Skills Training. Int. J. Environ. Res. Public Health 20, 4066. https://doi.org/10.3390/ijerph20054066

Fazel S, Vazquez-Montes MDLA, Molero Y, et al. 2023. Risk of death by suicide following self-harm presentations to healthcare: development and validation of a multivariable clinical prediction rule (OxSATS) BMJ Ment Health;26:e300673. 

Freeman D, Rosebrock L, Waite F, et al. 2023. Virtual reality (VR) therapy for patients with psychosis: Satisfaction and side effects. Psychological Medicine, 53(10), 4373-4384. doi:10.1017/S0033291722001167

Macdonald O, Green A, Walker A, et al. 2023. Impact of the COVID-19 pandemic on antipsychotic prescribing in individuals with autism, dementia, learning disability, serious mental illness or living in a care home: a federated analysis of 59 million patients’ primary care records in situ using OpenSAFELY. BMJ Ment Health;26:e300775. 

Meisinger C, Freuer D. 2023. Understanding the causal relationships of attention-deficit/hyperactivity disorder with mental disorders and suicide attempt: a network Mendelian randomisation study. BMJ Ment Health; 26:e300642.

Morales-Muñoz I, Mallikarjun PK, Chandan JS, et al. 2023. Impact of anxiety and depression across childhood and adolescence on adverse outcomes in young adulthood: a UK birth cohort study. The British Journal of Psychiatry, 222(5), 212-220. 

NICE. 2023. Alcohol-use disorders: diagnosis and management. Quality standard [QS11] Published: 24 August 2011 Last updated: 06 July 2023

NICE. 2023. Depression in adults. Quality standard [QS8] Published: 29 March 2011 Last updated: 29 June 2023 

NICE. 2023. Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal). Technology appraisal [TA899]. Published: 06 June 2023

NICE. 2023. Guided self-help digital cognitive behavioural therapy for children and young people with mild to moderate symptoms of anxiety or low mood: early value assessment

Health technology evaluation. Reference number:HTE3 Published: 08 February 2023. Last updated:  05 September 2023

Paljärvi T, Herttua K, Taipale H, et al. 2023. Cause-specific excess mortality after first diagnosis of bipolar disorder: population-based cohort study. BMJ Ment Health; 26:e300700. 

Raison CL, Sanacora G, Woolley J, et al. 2023. Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA. Sep 5;330(9):843-853. doi: 10.1001/jama.2023.14530.

Zarbo C, Rota M, Calza S, DiAPAson Collaborators, et al. 2023. Ecological monitoring of physical activity, emotions and daily life activities in schizophrenia: the DiAPAson study. BMJ Ment Health; 26:e300836.